vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2023 to Q4 2025

Type / Class
Equity / Class A Common Stock, par value $0.01 per share
Symbol
VTVT on Nasdaq
Underlying class
Class A Common Stock ("Common Stock")
Shares outstanding
4,080,222
Price per share
$42.38
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
1,283,621
Total reported value
$51,331,630
% of total 13F portfolios
0%
Share change
+64,343
Value change
+$2,953,481
Number of holders
26
Price from insider filings
$42.38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Samsara BioCapital, L.P. 9.9% 0% $12,001,117 +$1,803,961 403,942 +18% Srinivas Akkaraju 08 Dec 2025
Invus Global Management, LLC 9.4% -5.9% $9,179,310 +$1,051,154 393,098 +13% Raymond Debbane 30 Sep 2025
Trails Edge Capital Partners, LP 9.9% $5,108,040 340,536 Trails Edge Capital Partners, LP 29 Aug 2025

As of 31 Dec 2025, 26 institutional investors reported holding 1,283,621 shares of vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT). This represents 31% of the company’s total 4,080,222 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT) together control 31% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
SAMSARA BIOCAPITAL, LLC 7.3% 298,496 -20% 1.2% $11,936,855
FMR LLC 6.6% 268,856 +39% 0% $10,751,551
Trails Edge Capital Partners, LP 5.7% 231,000 0% 2.3% $9,237,690
Siren, L.L.C. 4% 163,000 0% 0.19% $6,518,370
BAKER BROS. ADVISORS LP 3.6% 148,314 0% 0.03% $5,931,077
VANGUARD GROUP INC 2% 83,400 +77% 0% $3,335,166
GEODE CAPITAL MANAGEMENT, LLC 0.69% 28,194 +84% 0% $1,127,567
683 Capital Management, LLC 0.45% 18,268 0.06% $730,537
NORTHERN TRUST CORP 0.39% 16,052 +14% 0% $641,919
BlackRock, Inc. 0.26% 10,606 +115% 0% $424,134
Pathstone Holdings, LLC 0.15% 6,073 0% $242,876
GOLDMAN SACHS GROUP INC 0.14% 5,531 0% $221,185
UBS Group AG 0.04% 1,668 -44% 0% $66,703
Tower Research Capital LLC (TRC) 0.03% 1,268 0% $50,707
OSAIC HOLDINGS, INC. 0.03% 1,120 -31% 0% $44,787
MORGAN STANLEY 0.02% 977 +31% 0% $39,071
Farther Finance Advisors, LLC 0.01% 279 0% $11,157
CITIGROUP INC 0.01% 244 +24300% 0% $9,758
BESSEMER GROUP INC 0% 112 0% $4,000
Activest Wealth Management 0% 50 0% 0% $2,000
CoreCap Advisors, LLC 0% 45 0% 0% $1,800
Parallel Advisors, LLC 0% 38 0% 0% $1,520
Sunbelt Securities, Inc. 0% 15 0% 0% $600
BNP PARIBAS FINANCIAL MARKETS 0% 9 0% 0% $360
BANK OF AMERICA CORP /DE/ 0% 4 +300% 0% $160

Institutional Holders of vTv Therapeutics Inc. - Class A Common Stock, par value $0.01 per share (VTVT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,283,621 $51,331,630 +$2,953,481 $39.99 26
2025 Q3 988,279 $23,052,921 +$9,364,357 $23.35 23
2025 Q2 587,143 $8,742,344 +$226,154 $15.00 21
2025 Q1 571,712 $9,902,095 +$353,201 $17.32 20
2024 Q4 551,416 $7,570,090 +$133,643 $13.81 17
2024 Q3 542,324 $7,337,088 +$2,516,893 $13.56 20
2024 Q2 348,140 $6,148,038 +$252,272 $17.66 19
2024 Q1 333,650 $7,850,341 +$6,240,904 $23.53 19
2023 Q4 68,620 $788,715 +$781,835 $11.50 14
2023 Q3 600 $287 +$287 $0.48 1